Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-8-16
pubmed:abstractText
The purpose of this study was to determine the effect of the addition of cilostazol to aspirin plus clopidogrel on platelet aggregation after intracoronary stent implantation. Twenty patients who underwent coronary stent placement were randomly assigned to therapy with aspirin plus clopidogrel (dual-therapy group, n = 10) or aspirin plus clopidogrel plus cilostazol (triple-therapy group, n = 10). A loading dose of clopidogrel (300 mg) and cilostazol (200 mg) was administered immediately after stent placement, and clopidogrel (75 mg/day) and cilostazol (100 mg twice daily) were given for 1 month. Platelet aggregation in response to adenosine diphosphate (ADP; 5 and 20 micromol/L) or collagen and P-selectin (CD-62P) expression was assayed at baseline, 2 hours, 24 hours, 1 week, and 1 month after stent placement. Inhibition of ADP-induced platelet aggregation was significantly higher in patients receiving triple therapy than those receiving dual therapy from 24 hours after stent placement, and inhibition of collagen-induced platelet aggregation was significantly higher in the triple-therapy group beginning 1 week after stent placement. P-Selectin expression was significantly lower in the triple-therapy than dual-therapy group at 1 week and 30 days. In conclusion, compared with dual antiplatelet therapy, triple therapy after coronary stent placement resulted in more potent inhibition of platelet aggregation induced by ADP and collagen. These findings suggest that triple therapy may be used clinically to prevent thrombotic complications after coronary stent placement.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
610-4
pubmed:meshHeading
pubmed-meshheading:17697815-Aspirin, pubmed-meshheading:17697815-Biological Markers, pubmed-meshheading:17697815-Blood Vessel Prosthesis Implantation, pubmed-meshheading:17697815-Coronary Restenosis, pubmed-meshheading:17697815-Coronary Stenosis, pubmed-meshheading:17697815-Drug Therapy, Combination, pubmed-meshheading:17697815-Female, pubmed-meshheading:17697815-Flow Cytometry, pubmed-meshheading:17697815-Follow-Up Studies, pubmed-meshheading:17697815-Humans, pubmed-meshheading:17697815-Male, pubmed-meshheading:17697815-Middle Aged, pubmed-meshheading:17697815-Myocardial Revascularization, pubmed-meshheading:17697815-P-Selectin, pubmed-meshheading:17697815-Platelet Aggregation, pubmed-meshheading:17697815-Platelet Aggregation Inhibitors, pubmed-meshheading:17697815-Preoperative Care, pubmed-meshheading:17697815-Stents, pubmed-meshheading:17697815-Tetrazoles, pubmed-meshheading:17697815-Ticlopidine, pubmed-meshheading:17697815-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
pubmed:affiliation
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't